[Confirmation of a workable relationship between saliva and plasma phenytoin concentrations in man as measured by radioimmunoassay]. 1978

R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant

UI MeSH Term Description Entries
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012463 Saliva The clear, viscous fluid secreted by the SALIVARY GLANDS and mucous glands of the mouth. It contains MUCINS, water, organic salts, and ptylin. Salivas

Related Publications

R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
December 1975, Clinical pharmacology and therapeutics,
R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
February 1980, Research communications in chemical pathology and pharmacology,
R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
April 1977, British journal of clinical pharmacology,
R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
August 1977, Clinica chimica acta; international journal of clinical chemistry,
R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
August 1975, British journal of clinical pharmacology,
R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
January 1983, Pediatric pharmacology (New York, N.Y.),
R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
July 1984, Clinical pharmacology and therapeutics,
R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
January 1982, Journal of clinical pharmacology,
R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
May 1970, The Journal of endocrinology,
R Alric, and J P Blayac, and C Negre, and M Baldy-Moulinier, and P Passouant
October 1974, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!